Repositive unveils molecular search functionality for its Cancer Models Platform at ELRIG Drug Discovery
This innovative new feature will further support the preclinical development of precision cancer therapies.
5th November 2019, Repositive – the Cambridge-based company that has curated the world’s largest directory of preclinical cancer models – is unveiling molecular search functionality for its Cancer Models Platform today at ELRIG Drug Discovery (booth B13, 5-6 November, Liverpool, UK). The first version of this innovative feature enables pharma and biotech scientists to search Repositive’s cancer model directory by their gene of interest and explore different mutations available, including each mutation’s effects on the protein amino acid sequence and pathogenicity prediction, amongst others, to ensure they source a cancer model with the right molecular profile for their preclinical study. The Repositive cancer model directory currently catalogues more than 5,300 models from 19 specialist preclinical oncology CRO partners across the world.
With pharma and biotechs increasingly focusing on patient stratification to develop more effective treatments, researchers need to source preclinical models with molecular profiles that match their target patient population. However, it remains a challenge for researchers to compare the molecular characteristics of preclinical cancer models from different CROs in order to identify those that will be most predictive of patient response.
In addition to curating the world’s largest directory of preclinical cancer models, Repositive’s molecular biologists and bioinformaticians have standardised the metadata for over 5,300 models, which is publicly available to browse via its Cancer Models Platform. Repositive’s platform speeds up the process of finding the right cancer model for pharma and biotech scientists by making it quicker and easier to compare the characteristics of cancer models across its global CRO partner network.
To further assist researchers in their hunt for the right preclinical model, Repositive has launched an innovative molecular search function for its platform. By simply selecting a mutation of interest from the dropdown menu, in addition to the desired model type, tumour primary site and cancer subtype, the new feature enables researchers to easily shortlist models that match their criteria. Researchers can then compare the curated genomic and molecular metadata for each model side-by-side, such as the nucleotides at the reference and alternative allele, as well as each mutation’s location, impact, maximum frequency and consequence, including any resulting amino acid changes. When a model of interest has been identified, biopharmas can simply get in touch with the Repositive Team via the platform to request additional model data and be put in touch with the CRO offering the model to start project planning discussions.
“Molecular search is something we’re particularly thrilled to bring to our platform as we know just how helpful it will be to drug developers working on precision cancer therapies. We’ve had some promising feedback while testing the new feature with our biopharma community and are looking forward to showcasing it to researchers at our booth at ELRIG Drug Discovery.” said Fiona Nielsen, CEO of Repositive. “But this is just the tip of the iceberg – we’re already busy enhancing our search functionality even further to ensure scientists have access to all the data they need directly on our platform, in order to make an informed decision about their preclinical model.”
Pharma and biotech researchers can try the new molecular search at the Repositive booth (B13) at ELRIG Drug Discovery or by visiting Repositive's Cancer Models Platform: https://bit.ly/2NlyQlN
